- Home
- GPRK vs CRVS Comparison
GPRK vs CRVS Comparison
Compare GPRK & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPRK
- CRVS
- Stock Information
- Founded
- GPRK 2002
- CRVS 2014
- Country
- GPRK Colombia
- CRVS United States
- Employees
- GPRK N/A
- CRVS N/A
- Industry
- GPRK Oil & Gas Production
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- GPRK Energy
- CRVS Health Care
- Exchange
- GPRK Nasdaq
- CRVS Nasdaq
- Market Cap
- GPRK 397.8M
- CRVS 459.0M
- IPO Year
- GPRK N/A
- CRVS 2016
- Fundamental
- Price
- GPRK $7.95
- CRVS $8.79
- Analyst Decision
- GPRK Hold
- CRVS Strong Buy
- Analyst Count
- GPRK 1
- CRVS 4
- Target Price
- GPRK $8.50
- CRVS $13.75
- AVG Volume (30 Days)
- GPRK 1.1M
- CRVS 1.0M
- Earning Date
- GPRK 11-05-2025
- CRVS 11-04-2025
- Dividend Yield
- GPRK 1.51%
- CRVS N/A
- EPS Growth
- GPRK N/A
- CRVS N/A
- EPS
- GPRK 0.65
- CRVS N/A
- Revenue
- GPRK $525,938,000.00
- CRVS N/A
- Revenue This Year
- GPRK N/A
- CRVS N/A
- Revenue Next Year
- GPRK N/A
- CRVS N/A
- P/E Ratio
- GPRK $11.63
- CRVS N/A
- Revenue Growth
- GPRK N/A
- CRVS N/A
- 52 Week Low
- GPRK $5.66
- CRVS $2.54
- 52 Week High
- GPRK $11.72
- CRVS $9.55
- Technical
- Relative Strength Index (RSI)
- GPRK 56.58
- CRVS 63.66
- Support Level
- GPRK $7.50
- CRVS $8.34
- Resistance Level
- GPRK $8.13
- CRVS $9.22
- Average True Range (ATR)
- GPRK 0.30
- CRVS 0.55
- MACD
- GPRK -0.07
- CRVS 0.01
- Stochastic Oscillator
- GPRK 41.67
- CRVS 83.41
About GPRK Geopark Ltd
GeoPark Ltd is a Latin American oil and gas exploration and production company with assets in Colombia, Ecuador, Chile, Brazil, and Argentina. The company generates revenue from the sale of crude oil, condensate, and natural gas, net of value-added tax and discounts related to the sale and overriding royalties due to the ex-owners of oil and gas properties where the royalty arrangements represent a retained working interest in the property.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).